1.76
0.56%
-0.01
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Wall Street SWOT: aTyr Pharma stock rides wave of clinical progress amid risks - Investing.com
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 55.5% - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Aarti Drugs gets 7 observation from USFDA for Tarapur plant - NewsDrum
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
A look into Atricure Inc (ATRC)’s deeper side - SETE News
First Light Asset Management LLC Grows Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Aarti Drugs shares trade lower after 7 observations from USFDA - Moneycontrol
Buying Buzz: Atyr Pharma Inc [ATYR] Director SCHIMMEL PAUL purchases 52,300 shares of the company - Knox Daily
Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quest Partners LLC Has $40,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
Atyr PHARMA (ATYR) versus Its Competitors Critical Survey - Defense World
Aster DM Health, Quality CARE inching closer to a merger deal - The Economic Times
Atyr PHARMA (ATYR) and Its Rivals Head to Head Analysis - Defense World
Atyr PHARMA (NASDAQ:ATYR) versus Exscientia (NASDAQ:EXAI) Critical Survey - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1% - MarketBeat
Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily
ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha
Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily
Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News
Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex
Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN
Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World
Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News
Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World
Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World
Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK
aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire
aTyr Pharma to Participate in September Investor Conferences - StockTitan
ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com
Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com
Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex
aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com
ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com
Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World
Q3 2024 Earnings Forecast for Atyr PHARMA INC Issued By HC Wainwright (NASDAQ:ATYR) - MarketBeat
ATYR’s Stock Market Adventure: 41.84% YTD Growth Amidst Volatility - The InvestChronicle
ATYR (aTyr Pharma) Cash From Discontinued Investing Activit - GuruFocus.com
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - MarketBeat
Atyr PHARMA INC to Post FY2028 Earnings of $4.72 Per Share, HC Wainwright Forecasts (NASDAQ:ATYR) - Defense World
Atyr PHARMA (NASDAQ:ATYR) Receives “Outperform” Rating from Royal Bank of Canada - Defense World
Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results, Beats Expectations By $0.01 EPS - Defense World
Atyr PHARMA (NASDAQ:ATYR) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Piper Sandler maintains Overweight rating on aTyr Pharma shares By Investing.com - Investing.com UK
Atyr Pharma: Q2 Earnings Snapshot - CT Insider
Atyr Pharma: Q2 Earnings Snapshot - Darien Times
Atyr Pharma: Q2 Earnings Snapshot - CTPost
ATYR (aTyr Pharma) Profitability Rank : 1 (As of Mar. 2024) - GuruFocus.com
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024 - InvestorPlace
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024 - MSN
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update - BioSpace
ATYR (aTyr Pharma) 3-Year EPS without NRI Growth Rate : 19.00% (As of Mar. 2024) - GuruFocus.com
Atyr Pharma: Q2 Earnings Snapshot - Houston Chronicle
자본화:
|
볼륨(24시간):